Ibio Inc
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Ibio's stock with a target price of $3.40, indicating significant growth potential.
Financial Health
Ibio Inc has limited revenue and cash flow, indicating challenges in financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IBIO
AI-Driven Drug Discovery
These groundbreaking companies are redefining pharmaceutical research with artificial intelligence. Each has been carefully selected by our analysts for their potential to develop life-saving drugs faster and more efficiently than traditional methods allow.
Published: June 17, 2025
Explore BasketPenny Stocks to Watch
Looking for the next big thing at a small price? This carefully selected group of stocks under $5 has caught the attention of professional hedge funds. These hidden gems might offer significant growth potential for investors willing to take on some risk.
Published: May 27, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Catalysts to Watch
Clinical milestones, regulatory updates or partnership deals can move the share price sharply, though outcomes are uncertain and can go either way.
Partnerships Matter
Collaborations and licensing can de‑risk programmes and provide funding, but success depends on deal terms and execution.
Balance Sheet Focus
With a market cap around $22m, cash runway and potential dilution are central considerations; smaller firms often need additional funding.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
